Funded Medical Projects


Michael’s Cause contributes 100% of proceeds for programs, grants, and projects that support its mission to provide and appropriate funds that benefit the community for which it serves. Funds are not to be used for institutional, administrative, overhead, or indirect costs, only direct patient care or research.

$100,000 - 08/04/2016 - DMD Therapeutics - Relaxin - Dr. Ronald Berenson. Anti-Fibrotic agent to help with fibrosis in treating Duchenne Muscular Dystrophy


$70,000 - 03/20/2016 - DDID 100108 Oteoprotegerin (OPG): Dr. Jerome Frenette - OPG Bone Protector rescues fast twitch muscles

- 05/12/2015 - DDID 10096 Reveragen VBP15. This research project will be an alternative to commonly used glucocorticoids with less side effects. 


$70,000 - 11/6/2014 - Phase I/IIa Follistatin Gene Therapy Trial. Dr. Jerry Mendell, Director Center for Gene Therapy at Nationwide Children's Hospital, Columbus Ohio.  Gene therapy is revolutionary science in our continued fight for better treatments and a future cure for Duchenne.


$70,000 - Halo Therapeutics: HT100 Phase 1/2, Anti Fibriotic agent for the treatment of Duchenne Muscular Dystrophy.

$40,000 - 12/14/2015 - DDID # 100084 - Seratonin Modulators in Zebra Fish - Dr Louis Kunkel (Boston Childrens) - Effects of Seratonin Modulators in Zebra Fish and Mice

$50,000 - 03/08/2015 DMD Therapeutics - Osteoprotegerin. Dr. Ron Berenson / Dr. Carlo Rago.


$50,000 - 04/07/2017 Montelukast University of Missouri - Montelukast. Dr.Donsheng Duan / Dr. Bob McDonald.


$37,500 - 04/07/2017 Kennedy Krieger Institute Myoblast Therapy - Myoblasts derived from IPSC's. Dr. Kathryn Wagner


$35,000 - 10/21/2017 Team Joseph - Dr. John Lynn Jeffries. Phrixus Pharmaceuticals. Carmaseal


$30,000 12/27/2017 - DMD Therapeutics. Dr. Ron Berenson/Dr. Carlo Rago - OPG Eficacy Study

$30,000 - Halo Therapeutics: HT100 Phase 1/2, Anti Fibriotic agent for the treatment of Duchenne Muscular Dystrophy.

$30,000 – Preparation of the Anti-Fibrotic Halofuginone for use in a multi-center Phase II clinical trial. Halofuginone is an anti-fibrotic and muscle regeneration promoter. To date 1.1 million dollars has been funded to help this project get to phase II clinical trial. Halo Press Release.

$25,000 - 01/15/2017 DMD Therapeutics - Osteoprotegerin. Dr. Ron Berenson / Dr. Carlo Rago.

$25,000 - 03/08/2015 DMD Therapeutics - Osteoprotegerin. Dr. Ron Berenson / Dr. Carlo Rago.

$25,000 - DDID #100087 - Supressing the level of inflammation in the muscle - Keith Foster, University of Reading, UK


$25,000 - 05/15/2018 - Oteoprotegerin (OPG) - Dr. Jerome Frenette University of Laval. OPG Bone Protector Rescues Fast Twitch Muscles.

$24,840 - 09/20/2017 University of Missouri OPG - Dr. Dongsheg Duau. OPG Confirmation Study - funding to Ryans Quest who paid Univ of Missouri

$20,000 – 10/9/2014 Natural hormone study that has effects on muscle that may benefit patients with DMD.  In animal studies it has been demonstrated to regenerate damaged skeletal muscle.

$20,000 - DDID #100077 Multicenter randomized double-blind dose titration phase II study in patients with Duchenne muscular dystrophy to evaluate the efficacy and the tolerability of the combinations of Ibuprofen and Isosorbide Dinitrate.  Conducted by Emillio Clementi, MD Phd, professor of pharmacology, Department of Biomedical and Clinical Sciences, University of Milano-E.Medea Scientific Institute.


$15,000 - 05/15/2018 - Quercetin - Dr. Josh Selsby University of Iowa: Effects of a Quercetin Cocktail.

$15,000 - 08/08/2016 Phrixus Pharmaceuticals - Carmeseal - Clinical Trial - for treatment of heart failure and respiratory dysfunction in DMD

$15,000 - 04/15/2016 - Project Goldilocks: Jackson Laboratories - Better Mouse Model for Duchenne testing.

$15,000 - DDID #100071 Quercetin - Determining the mechanisms whereby a Quercetin enriched diet interrupts disease process in DMD.


$15,000 - Hugo W. Moser Research Institute at Kennedy Kreiger for Duchenne Muscular Dystrophy Research


$10,350 - 09/27/2017 DMD Therapeutics. Dr. Ron Berenson/Dr. Carlo Rago - OPG Eficacy Study

$10,000 - 10/01/2015 - Grant/Donation - Hugo W. Moser - Hugo H Moser Research Laboratory - Fund Dr Wagner Laboratory for research.


$10,000 - 06/27/2015 - DDID # 100094 Plasma Micro RNA Profiling: Dr Julie Saba (Children's Hospital and Research Center at Oakland - S1P Lyaselnibitor Pilot in MDX Mice

$10,000 - Measurement of in vivo respiratory and cardiac function during dietary enrichment in animal models of DMD.

$10,000 – Muscle regeneration available research available with compounds delivered as nutraceutical. Using an unbiased screen a genetic pathway was identified and associated compounds that regenerate muscle in Duchenne Muscular Dystrophy mouse and fly models. Funding will assist in furthering research in this area.


$7,500 - Natural hormone which has the ability to regenerate muscle, reduce scarring, and improve cardiac function

$5,000 - 07/28/2015 - Treat NMD / Tact Review: Funding for Tact Review - Fund research for review committee on DMD research treatments


$5,000 - Assist in payment to O’Neill and Associates for their lobbying efforts to help further research in DMD.

$5,000 - Development of Dystrophin Independent Therapy for DMD.

$5,000 - Superior Mouse Model for DMD drug development.

$2,500 – Evaluation of small compounds that increase Utrophin levels for therapy of Duchenne Muscular Dystrophy. Utrophin is a protein and was found during research into Duchenne's muscular dystrophy. It is believed that producing this protein in the human body will help greatly with those affected by this disease.

$2,000 – The effects of Poloxamer-188 (Carmeseal) on cardiac and skeletal muscle function in MDX mice. Cardiac Function plays an important role in those affected by DMD. Funding will help further research with this drug to see hopeful benefit.

$1,000 – Duchenne Dashboard Phases V and VI. The Duchenne Dashboard allows foundations to co-identify co-understand and co-fund projects in order to conquer Duchenne Muscular Dystrophy. Funding in this area is necessary to maintain upgrades to the Dashboard.